Cerebrolysin around the world

The unusual position of Cerebrolysin

Cerebrolysin sits in an unusual epistemic position: more clinical experience than almost any other neuroactive peptide preparation, and more methodological controversy in mainstream Western literature than almost any other clinical product. Both readings are legitimate, and understanding why is part of the article's point.

The compound — a defined mixture of low-molecular-weight peptides and free amino acids derived from porcine brain protein hydrolysate — has been in clinical use since the 1970s. Approval status spans 50+ countries including Russia, China, Mexico, much of Eastern Europe, and Austria (where it's manufactured). Aggregate clinical use is in the tens of millions of patient-treatments.

The trial portfolio

The major Western-accessible Cerebrolysin trial portfolio includes:

• CARS-1 and CARS-2 in acute ischemic stroke — reported neurological improvement at 90 days vs placebo, with effect sizes that varied by subgroup.
• CASTA (Stroke 2012) — Asian population, ischemic stroke, similar pattern of subgroup-dependent effects.
• CAPTAIN-I and CAPTAIN-II in moderate-to-severe TBI — reported improvements on functional outcome scales.
• Multiple smaller trials in vascular dementia and Alzheimer's disease — heterogeneous results, generally with positive central tendencies.

The Cochrane review (Ziganshina et al., updated through 2020) concluded that cerebrolysin in acute ischemic stroke does not provide clear benefit on mortality or disability, with concerns about risk of bias in many included studies. The conclusion is meaningful, and the methodological concerns are real — but they don't account for the full clinical picture either.

What's hard about evaluating mixture pharmacology

Cerebrolysin's resistance to clean evidence-grading partly reflects the inherent challenge of mixture-based pharmacology. Modern drug-development frameworks are built around single-molecule entities with defined receptor targets and clean dose-response curves. A mixture of dozens of low-molecular-weight peptides plus free amino acids fits that framework poorly.

The mechanistic literature describes cerebrolysin as having BDNF-like activity, modulating glutamate-mediated excitotoxicity, and affecting endogenous protein clearance — multiple pathway effects from a multi-component mixture. Whether this is "imprecise pharmacology" or "broad neurotrophic-like activity" depends on the framework you bring.

The clinical-experience signal

One of the more interesting observations is that adoption has continued in countries where Cerebrolysin is approved despite the Cochrane skepticism. Several explanations are possible: clinicians in those countries see effects that don't show up in Cochrane-grade evidence, the compound has genuine effects that are real but smaller than RCT methodologies are powered to detect at population level, the regulatory frameworks of those countries differ in how they weight evidence, or a combination of all three.

The honest reading is probably that cerebrolysin has real clinical effects in the indications where it's used, that the effects are smaller than initial enthusiasm suggested, and that the methodological concerns the Cochrane reviews raise are legitimate while not invalidating the underlying clinical utility.

What we'd want to see

An ideal study would be a large, multi-center, methodologically rigorous Western RCT in a specific high-stakes indication (severe TBI, large-vessel stroke with delayed presentation) with adequate statistical power and pre-specified primary endpoints. Such a trial would clarify whether the clinical-experience signal in adopting countries reflects real but small effects or methodological artifact. The trial would be expensive, the manufacturer (Ever Pharma) is the most likely sponsor, and the result would be informative either way.